Table 2.
Summary of menthol pharmacokinetic parameters
| Parameter | mean±SD | 95% CI | CV% |
|---|---|---|---|
| Cmax (ng/mL) | 698.2±245.4 | (501.8 to 894.6) | 35.1 |
| Cmax (ng/mL per mg/kg) | 361.8±80.8 | (297.2 to 426.5) | 22.3 |
| Tmax (h) | 5.3±2.4 | (3.3 to 7.2) | 45.3 |
| Tlag (h) | 2.0±1.0 | (1.2 to 2.8) | 50.0 |
| AUClast (ng/mL×h) | 3562.0±616.7 | (3068.5 to 4055.4) | 17.3 |
| AUC last (ng/mL×h per mg/kg dose) | 1951.3±602.8 | (1468.9 to 2433.7) | 30.9 |
| AUCtot (ng/mL×h) | 4039.7±583.8 | (3572.6 to 4506.9) | 14.4 |
| AUC total (ng/mL×h per mg/kg dose) | 2207.8±613.8 | (1716.7 to 2698.9) | 27.8 |
| %AUC extrapolated | 12.1±5.3 | (7.8 to 16.3) | 43.8 |
| MRT (h) | 7.8±1.2 | (6.8 to 8.8) | 15.4 |
AUC, area under the plasma concentration versus time curve; Cmax, apparent peak plasma concentration; CV, coefficient of variation MRT, mean residence time; Tlag, apparent lag time between PO administration and appearance of menthol in plasma; Tmax, time of Cmax.Figure 1 Mean (±95% CI) plasma concentration versus time data for menthol in a cohort of six children with irritable bowel syndrome given a single oral dose of peppermint oil containing approximately 83.0 mg of menthol (top panel) and individual plasma menthol concentration versus time data (bottom panel).